Logo for Alligator Bioscience

Alligator Bioscience Investor Relations Material

Latest events

Logo for Alligator Bioscience

Q1 2024

Alligator Bioscience
Logo for Alligator Bioscience

Q1 2024

6 May, 2024
Logo for Alligator Bioscience

Q4 2023

9 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Alligator Bioscience

Access all reports
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.